KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals Inc. is positioned favorably due to the anticipated strong launch of its oral plasma kallikrein inhibitor, sebetralstat, which is expected to differentiate itself within the stabilized on-demand hereditary angioedema market by offering a more convenient and effective treatment option. Recent survey data indicates that a significant majority of allergists and immunologists believe patients will utilize more treatments with an oral medication, supporting conservative revenue projections of approximately $400 million in worldwide sales at peak performance. Furthermore, the upcoming PDUFA date suggests a high likelihood of approval, which could lead to a swift adoption and potential premium pricing, enhancing the company's financial outlook despite increasing operating expenses.

KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million for FY3Q25, translating to a loss of $0.92 per share, reflecting ongoing financial challenges and indicating a lack of profitability that may persist throughout the drug's early launch phase. The potential failure of its lead candidate, sebetralstat, could jeopardize the company’s financial stability, as its current pipeline lacks viable alternatives for future growth and is contingent on the successful commercialization of this product. Furthermore, regulatory uncertainties surrounding FDA approval and market acceptance, coupled with the requirement for external capital to support continued operations and development, further complicate the company's outlook.